Journal of Clinical Medicine
Real-World Treatment Outcomes and Prognostic Factors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer: A Single-Center Study from a High-Volume Tertiary Chest Hospital
Par Abdülkadir Koçanoğlu, Oktay Ünsal, Fatih Kuş et 4 autres.
Contenu en anglais
Résumé
Background/Objectives: Epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) is a distinct molecular subgroup responsive to EGFR tyrosine kinase inhibitors (TKIs). This study evaluated real-world treatment outcomes and prognostic factors in patients with EGFR-mutated metastatic NSCLC.